Alnylam Pharmaceuticals · 1 day ago
Senior Associate Scientist, In Vivo Pharmacology
Cambridge, MA
Full-time
Onsite
Mid, Senior Level
$79K/yr - $112K/yr
3+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, seeking a passionate Senior Associate Scientist to join their in vivo Pharmacology team. The role involves conducting in vivo studies, managing data analysis, and collaborating within a dynamic team to support RNAi therapeutic delivery.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Hiring Manager
Jeannine Ripley
Responsibilities
Contribute to the design of and independently execute in vivo studies to evaluate and characterize molecules for RNAi therapeutic delivery to a diverse array of tissues in a variety of animal models
Conduct in vivo procedures in mice and rats, including therapeutic administration using established methodologies and tissue collections
Conduct routine assays such as qPCR, western blot, ELISA to support in vivo studies, and begin to develop and troubleshoot novel assays
Maintain safe and clean working environment by complying with procedures, rules, and regulations
Responsible for high quality data entry and data analysis in a timely manner and prepare clearly articulated experimental reports and presentations
Adapt quickly to changing priorities in a dynamic work environment
Effectively and pro-actively multi-task and operate in a team-based environment
Communicate openly and directly within and across teams and management and demonstrate the ability to effectively manage conflict
Qualification
Required
BS/MS in Biology, Animal/Veterinary Sciences, Cell/Molecular Biology, Biochemistry, or related field with 3-5 years of laboratory experience in an industrial or academic setting working with animals
Basic rodent in vivo skills (animal handling, subcutaneous/intravenous dosing, blood collection, and necropsy/tissue dissection expertise)
Excellent lab techniques and the ability to work independently are a prerequisite
Demonstrate keen knowledge of experimental design, underlying scientific principles, and the ability to rigorously and independently analyze results, propose future directions, and generate clear reports
Must be flexible, open to new tasks and challenges and able to work on tight deadlines
Exceptional interpersonal skills and the ability to function at a high capacity within a fast-paced team environment
Excellent attention to detail, organizational skills, eagerness to learn, and the ability to follow written and verbal instruction
Working knowledge of standard Microsoft Office applications including Excel, GraphPAD, Outlook, PowerPoint, and Word
Good documentation and record-keeping in compliance with ELN (Electronic Lab Notebook) guidelines required
Preferred
Experience in specialized in vivo techniques such as direct tissue injections or collections (IT, ICV, ICM, IVT, IA, OP, PO etc.) is a plus
Experience in molecular biology techniques including RNA/DNA/protein extraction, qPCR, Western blot, ELISA a plus
Benefits
Medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
H1B Sponsorship
Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
2025-12-22
2025-12-20
Company data provided by crunchbase